Morganceutical vs IQVIA Arbitration Overview

An arbitration case between Morganceutical and IQVIA over a Network Agreement dispute highlights issues with agreement provisions, withdrawal repercussions, and alleged economic dependence abuse. Claims were dismissed in early 2026, with procedural updates extending to April 2026. Financial risk for Morganceutical remains low, and IQVIA contests damages exceeding €1M. The case nears its conclusion with a strong defensive stance by IQVIA and minimal risk for Morganceutical.